Supernus Pharmaceuticals Acquires Adamas Pharmaceuticals, Firming its CNS Product Portfolio

Oct 11, 2021 By MarketDepth

Biotechnology Headlines Healthcare Investing What's Hot

Investor Relations meeting

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), announced Monday a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million). Adamas Pharmaceuticals stock jumped more than 70% after the acquisition announcement.

“This acquisition represents a significant step to further build a strong and diverse Parkinson’s disease portfolio, and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases. We have a proven track record of strong commercial execution, and look forward to building on GOCOVRI’s growth momentum so that more patients can benefit from access to Adamas’ innovative neurological therapies.”

Jack Khattar, President and CEO of Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.

“We are pleased that Supernus recognized the value created at Adamas and firmly believe this path forward is an excellent outcome for not only our shareholders, but all our stakeholders. With their shared commitment to helping patients affected by neurological diseases and their extensive resources, Supernus can continue to advance our mission and reach. I am extremely proud of Team Adamas for their hard work and dedication to get us to this point and am confident that partnering with Supernus will maximize the potential of our innovative therapies.”

Neil F. McFarlane, Chief Executive Officer of Adamas Pharmaceuticals, Inc.